MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
128.89
+2.65 (+2.10%)
At close: 04:00PM EDT
125.50 -3.39 (-2.63%)
Pre-Market: 07:29AM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close126.24
Open126.47
Bid0.00 x 800
Ask0.00 x 1100
Day's Range124.23 - 129.24
52 Week Range115.03 - 217.25
Volume2,611,817
Avg. Volume3,433,528
Market Cap49.134B
Beta (5Y Monthly)1.69
PE Ratio (TTM)11.46
EPS (TTM)11.25
Earnings DateAug 01, 2023 - Aug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est218.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
2% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MRNA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    2 Healthcare AI Stocks to Buy on the Dip

    Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).

  • Simply Wall St.

    Moderna, Inc. (NASDAQ:MRNA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

    With its stock down 8.4% over the past week, it is easy to disregard Moderna (NASDAQ:MRNA). However, a closer look at...

  • ACCESSWIRE

    Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting

    Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL.

  • Motley Fool

    If You Invested $2,500 in Moderna in 2019, This Is How Much You Would Have Today

    You'd have a lot more money, but only if you resisted the temptation to take the initial profits.

  • The Wall Street Journal

    Next Covid Boosters to Target New Strain

    Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.

  • Reuters

    UPDATE 1-Moderna says looking for opportunities in China after registering legal entity

    U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China," a spokesperson said in response to a query from Reuters.

  • Reuters

    Moderna says looking for opportunities in China after registering legal entity

    BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China," a company spokesperson said in response to a query from Reuters.

  • American City Business Journals

    Biggest gainers, decliners since the pandemic among Mass. public companies

    Three years since the pandemic upended the economy, here are the Massachusetts public companies that made it through in the best — and worst — shape.

  • Investor's Business Daily

    Is Moderna Stock A Buy After Unexpectedly Turning A First-Quarter Profit?

    Is Moderna stock a buy after the company reported a 19-cent gain in the first quarter vs. calls for losses? Is MRNA stock a buy?

  • Simply Wall St.

    Possible Bearish Signals With Moderna Insiders Disposing Stock \

    The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...

  • InvestorPlace

    7 Stocks That Even Company Insiders are Selling

    Insider buying, or the legal, reported purchase of shares in a company by its C-suite/board members/large shareholders, is considered a bullish signal. However, does that mean it is best to sell/avoid stocks insiders are selling? Put simply, it depends. Heavy insider selling, or even a lack of insider buying, can sometimes be a sign that those most “in the know” at a company are not very confident in its future prospects. Then again, much like with “outsider” investors, lack of confidence isn’t

  • American City Business Journals

    Durham firm inks billion-dollar deal with Novo Nordisk to discover new treatments

    A life sciences company in Durham has secured a major partnership to discover new gene therapy treatments.

  • TheStreet.com

    Moderna Spikes Amid Covid Fears, but Is It Just a False Positive?

    The Moving Average Convergence Divergence (MACD) oscillator is below the zero line telling us that MRNA lacks trend strength. In this daily Point and Figure chart of MRNA, below, I can see a potential upside price target in the $179 area. This weekly Point and Figure chart of MRNA, below, shows us the same $179 price target as the daily chart above.

  • Yahoo Finance Video

    Moderna shares react to Covid resurgence news in China

    Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.

  • Motley Fool

    Is Moderna Stock a Buy Now?

    Biotech giant Moderna (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines. Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue. Is Moderna's stock worth considering, especially at current levels?

  • Zacks

    Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?

    Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

  • Motley Fool

    3 Stocks You'll Be Glad You Bought at These Prices

    The good news is you really don't have to -- and you still can win in the stock market. The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic. Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story.

  • Zacks

    Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

    Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

  • InvestorPlace

    Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich … or Broke.

    These biotech stocks are swinging for the fences. They may hit homers, they may strike out. But you’ll definitely want to watch them. Biotech stocks have been a high risk, high reward proposition in recent years. Many biotech companies soared high during the pandemic only to crash hard in its aftermath. We now search through the wreckage to see which will soar again, and which are best left for dead. For an investor who wants stability and low risk, there are plenty of big biotech stocks out the

  • Motley Fool

    Biotech Stocks Are Already Risky -- Now There Are 3 New Headwinds to Face in 2023

    Biotech investors love to take on oodles of risk in hopes of getting an outsized reward when one of their bets finally pays off. While NHPs account for only 0.5% of the animal models used in biomedicine, biotechs and other researchers in the U.S. have faced a shortage of NHPs since at least 2019.

  • ACCESSWIRE

    Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

    Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), presented at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.

  • Motley Fool

    Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%

    Moderna (NASDAQ: MRNA) surprised investors last quarter when it didn't incur a loss despite a significant drop in sales. For the first three months of 2023, Moderna's revenue totaled just under $1.9 billion, which is just a fraction of the $6.1 billion it reported in the same period last year. Meanwhile, its operating expenses, totaling $2.2 billion, rose by more than 21%.

  • Motley Fool

    3 Magnificent Growth Stocks to Buy to Help Build a Millionaire Portfolio

    It's never too early to start building a portfolio that may eventually make you a millionaire. Today, many growth stocks are suffering, but in some cases, prospects over time remain bright. Amazon (NASDAQ: AMZN) was on an earnings roll, delivering gains in net income year after year -- until last year, when the company swung to a loss for the first time since 2014.

  • Insider Monkey

    Here’s Why You Should Hold Moderna (MRNA)

    Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […]

  • Motley Fool

    Ready to Buy the Dip? This Biotech Stock Is a Smart Buy

    Moderna (NASDAQ: MRNA) saw its shares jump in 2021 and 2022 on the back of strong sales of its COVID-19 vaccine Spikevax. Spikevax helped prove to the world the effectiveness of messenger RNA (mRNA) technology. The company advanced three COVID-19 vaccines from phase 1 to commercial status in a year.